Erin McEvoy

Two recent studies examined the link between cannabis use and increased psychosis among other mental health disorders, and some results reportedly contrasted with currently held notions.

With bipartisan support in both the House and the Senate, the Secure and Fair Enforcement (SAFE) Banking Act was refiled this week.

Filmed onsite at Cannabis Science Conference Spring 2023, Kim Stuck, founder and CEO of Allay Consulting, shares her unique insights and experiences in the industry.

Filmed onsite at Cannabis Science Conference Spring 2023, Eloise Theisen shares perspectives and insider information from her profession.

The legislature of Hawaii this week approved a non-binding resolution encouraging the governor to create a clemency program for prior cannabis convictions.

Canna Boot Camp Spring 2023 was held at ChemHistory, a premier quality control testing laboratory in Milwaukie, Oregon. In this onsite interview, we speak with Business Director Alex Hoggan.

After serving their country, where do veterans find support once they’re home? Even after a tour of duty ends, the battle may be just beginning. Wounds, both visible and unseen, can make returning to civilian life a new struggle, especially with limited treatment options. However, as Canadian veteran, founder of Marijuana for Trauma, and cannabis advocate Fabian Henry explains, veterans need not struggle alone. After finding relief in cannabis to treat his own PTSD, Henry set out to help ensure no other veterans feel desperate and abandoned. Using his own path to healing as an example, Henry pushed back against the stigma around cannabis and encourages it as a therapy. In this interview, he shares how he brings veterans together into the difficult but beneficial process of holistic healing with cannabis as a catalyst.

Carly Bader of Willow Industries goes in-depth into her presentation at the cultivation track at Cannabis Science Conference Spring 2023.

Dustin Sulak, DO, founder of Healer and Integr8 Health, served as one of the keynote speakers at Cannabis Science Conference Spring 2023.

A recent study of a psychedelic compound found in ayahuasca produced new brain scans showing its impacts on the brain.

How much does hemp live up to its advertised potential as a versatile, sustainable crop and what is blocking its path to realizing its full abilities?

The Nova Scotia House of Assembly recently heard a petition to cover the cost of CBD-based medications for certain conditions.

To help clinicians and patients navigate cannabinoid-based medications (CBM), Cannabis and Cannabinoid Research published guidelines based on reviews of studies on CBM and chronic pain.

Recent reports on jobs and banking reveal the latest changes affecting the cannabis industry.

Two Colorado-based hemp companies and one tobacco company are joining forces to pursue FDA-approval for a new botanical drug.

The field of cannabis horticulture is ever-evolving and offers many opportunities for innovation and experimentation. In this interview, Jessica Lubell-Brand, PhD, professor of horticulture at the University of Connecticut with the Department of Plant Science and Landscape Architecture provides insights into the findings of her laboratory’s recent studies of the “retipping” method of propagating cannabis. She also shares details on her current research with cannabis breeding techniques and how studies like these can benefit the future of cannabis growing.

Let's hear what analytical track program chair Julie Kowalski is most excited about at Cannabis Science Conference Spring 2023!

In April 2023, two cannabis testing laboratories launched a certification program to promote higher standards for cannabis testing laboratories across the country.

Bipartisan legislation was recently reintroduced to remove barriers preventing veterans accessing medical cannabis as recommended by health care providers at the VA.

A pharmaceutical company, Vantage Hemp Co., announced it recently submitted two Drug Master Files (DMFs) to the Food and Drug Administration.

One recently published study suggests that a cannabis sublingual spray may be beneficial in the treatment of type 2 diabetes.

What is Cherissa Jackson, RN most excited about as the medical track program chair for Cannabis Science Conference?

A recently published case study documents one chronic pain patient’s reduction of prescribed pain medication after being referred to a medical cannabis registry. Prescribed cannabis-based medicinal products (CBMPs) have been legal in the UK since 2018.

Oregon Psilocybin Services (OPS) issued first psilocybin manufacturer license since accepting applications earlier this year.

Read an interview from Pharmaceutical Technology Europe exploring how the European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical grade manufacturing of cannabis-based medicines.

Initial findings from a recent study suggested that cannabidiol (CBD) derivatives made naloxone treatment more effective, even against the opioid fentanyl.

The study will examine consumption and health of the participants after purchasing selected cannabis products from controlled cultivation under regulated conditions.

In late March, the Wine & Spirits Wholesalers of America submitted a letter to congressional leadership expressing its support for cannabis legalization that uses regulatory frameworks similar to those of the alcohol industry.

The Food and Drug Administration (FDA) will hold an educational webinar on cannabis and cannabis-derived products for healthcare practitioners in late March.

Health and safety notices were issued in two states due to concerns about contamination exposure.